Re‐visiting Busulfan Disposition: Significance and Clearance Mechanisms

Alan L. Myers(The University of Texas Health Science Center), Romi Ghose(University of Houston), Inas A. Abdallah(University of Sadat City), Yan‐Ping Zhang(University of Miami), Mark Kramer(Harvard University Press), Börje S. Andersson(The University of Texas MD Anderson Cancer Center), Hazem E. Hassan(University of Maryland, Baltimore), Pankajini Mallick(University of Houston)

The FASEB Journal

April 1, 2015

10.1096/fasebj.29.1_supplement.940.2

Cited by 1

Related Papers

Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

|Blood|1997|1.2k

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.

|Journal of Clinical Oncology|1998|927

Angiogenesis in wound repair: Angiogenic growth factors and the extracellular matrix

|Microscopy Research and Technique|2002|733

Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

|Blood|2001|570

Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts [see comments]

|Blood|1995|539